Tadamitsu Kishimoto Selected Research

tocilizumab (atlizumab)

1/2022	IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19.
1/2021	Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms.
1/2021	IL-6: from arthritis to CAR-T-cell therapy and COVID-19.
1/2020	IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
1/2019	Discovery of IL-6 and Development of Anti-IL-6R Antibody.
1/2018	Interleukin (IL-6) Immunotherapy.
1/2016	Immunotherapeutic implications of IL-6 blockade for cytokine storm.
1/2015	Therapeutic uses of anti-interleukin-6 receptor antibody.
1/2015	Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis.
1/2015	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tadamitsu Kishimoto Research Topics

Disease

30	Rheumatoid Arthritis 05/2022 - 01/2002
27	Inflammation (Inflammations) 11/2022 - 01/2002
19	Neoplasms (Cancer) 11/2022 - 02/2002
19	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2022 - 08/2004
18	Infections 11/2022 - 11/2002
17	Castleman Disease (Castleman's Disease) 05/2022 - 01/2002
15	Arthritis (Polyarthritis) 01/2021 - 06/2002
13	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 02/2004
10	Cytokine Release Syndrome 01/2022 - 01/2015
8	Wounds and Injuries (Trauma) 01/2021 - 02/2014
6	Colitis 11/2018 - 11/2002
5	COVID-19 01/2022 - 01/2020
5	Sepsis (Septicemia) 01/2021 - 01/2016
5	Crohn Disease (Crohn's Disease) 02/2011 - 11/2002
4	Takayasu Arteritis (Arteritis, Takayasu's) 01/2020 - 01/2013
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2019 - 07/2008
4	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/2018 - 01/2015
4	Systemic Juvenile Rheumatoid Arthritis 04/2014 - 11/2006
3	Systemic Scleroderma (Systemic Sclerosis) 05/2022 - 12/2010
3	Giant Cell Arteritis (Horton Disease) 01/2020 - 11/2018
3	Septic Shock (Toxic Shock Syndrome) 01/2019 - 10/2016
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2018 - 01/2009
3	Shock 01/2018 - 11/2002
3	Multiple Myeloma 01/2017 - 01/2002
3	Acute-Phase Reaction 01/2016 - 02/2014
3	Experimental Arthritis 08/2011 - 01/2003
3	Anemia 01/2011 - 12/2002
2	Immune System Diseases (Immune Disorders) 11/2022 - 05/2022
2	Pulmonary Hypertension 01/2021 - 05/2015
2	Hypoxia (Hypoxemia) 01/2021 - 05/2015
2	Pulmonary Arterial Hypertension 01/2021 - 05/2015
2	Reactive Arthritis (Reiter Disease) 01/2019 - 12/2009
2	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 01/2019 - 05/2010
2	Hematologic Neoplasms (Hematological Malignancy) 11/2018 - 05/2002
2	Multiple Sclerosis 07/2013 - 07/2010
2	Malignant Mesothelioma 01/2013 - 08/2011
2	Fever (Fevers) 01/2011 - 09/2010
2	Anorexia 01/2011 - 05/2008
2	Fatigue 01/2011 - 05/2008
2	Carcinogenesis 05/2010 - 01/2002
2	Asthma (Bronchial Asthma) 06/2007 - 02/2005
2	Reperfusion Injury 05/2007 - 02/2005
2	Glomerulonephritis 02/2004 - 12/2002
1	Interstitial Lung Diseases (Interstitial Lung Disease) 05/2022
1	Neuromyelitis Optica (Devic's Disease) 05/2022
1	Communicable Diseases (Infectious Diseases) 05/2022
1	Breast Neoplasms (Breast Cancer) 11/2021
1	Neoplasm Metastasis (Metastasis) 11/2021
1	Burns 01/2020
1	Bacterial Infections (Bacterial Infection) 01/2020
1	Rheumatic Diseases (Rheumatism) 01/2020
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020
1	Adult-Onset Still's Disease 01/2020

Drug/Important Bio-Agent (IBA)

58	Interleukin-6 (Interleukin 6)IBA 11/2022 - 01/2002
38	tocilizumab (atlizumab)FDA Link 01/2022 - 03/2005
33	CytokinesIBA 11/2022 - 01/2002
12	Monoclonal AntibodiesIBA 01/2020 - 11/2002
12	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2019 - 07/2003
8	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2021 - 08/2011
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2003
7	Biological ProductsIBA 01/2019 - 01/2002
6	RNA-Binding Proteins (RNA-Binding Protein)IBA 11/2022 - 01/2017
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2022 - 06/2002
6	Messenger RNA (mRNA)IBA 01/2020 - 04/2004
5	InterleukinsIBA 11/2021 - 04/2005
5	Therapeutic UsesIBA 01/2019 - 01/2009
5	Immunoglobulin G (IgG)IBA 02/2012 - 05/2002
4	AutoantibodiesIBA 05/2022 - 02/2004
4	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2022 - 03/2005
4	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2020
4	Pharmaceutical PreparationsIBA 01/2021 - 05/2008
4	Interleukin-17 (Interleukin 17)IBA 05/2015 - 03/2008
3	Immunomodulating AgentsIBA 11/2018 - 01/2016
3	LipopolysaccharidesIBA 01/2018 - 03/2014
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2011 - 06/2003
3	AntigensIBA 04/2010 - 06/2002
2	carbazoleIBA 01/2021 - 06/2013
2	Thalidomide (Thalomid)FDA Link 11/2018 - 01/2016
2	Dextrans (Dextran)FDA Link 11/2018 - 08/2015
2	sodium sulfate (sodium bisulfate)FDA LinkGeneric 11/2018 - 08/2015
2	LigandsIBA 01/2018 - 01/2011
2	MicroRNAs (MicroRNA)IBA 08/2015 - 01/2014
2	Biomarkers (Surrogate Marker)IBA 02/2012 - 04/2010
2	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2011 - 03/2005
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 02/2011 - 01/2003
2	C-Reactive ProteinIBA 01/2011 - 09/2010
2	AntibodiesIBA 06/2007 - 05/2002
2	Immunoglobulin M (IgM)IBA 01/2005 - 05/2002
1	Indomethacin (Indometacin)FDA LinkGeneric 04/2022
1	Long Noncoding RNAIBA 11/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2021
1	Semaxinib (SU5416)IBA 01/2021
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2021
1	Qingdai compoundIBA 01/2021
1	Environmental BiomarkersIBA 01/2021
1	Interleukin-8 (Interleukin 8)IBA 01/2020
1	Plasminogen Activator Inhibitor 1IBA 01/2020

Therapy/Procedure

22	Therapeutics 05/2022 - 12/2002
3	Off-Label Use 01/2015 - 02/2014
2	Immunotherapy 11/2022 - 05/2002